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ARTICLE

The evaluation of AZ66, an optimized sigma
receptor antagonist, against methamphetamineinduced dopaminergic neurotoxicity and memory
impairment in mice
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Abstract
Sigma (s) receptors have recently been identiﬁed as potential targets for the development of novel therapeutics
aimed at mitigating the eﬀects of methamphetamine. Particularly, s receptors are believed to mitigate some of
the neurotoxic eﬀects of methamphetamine through modulation of dopamine, dopamine transporters and body
temperature. Furthermore, recent evidence suggests that targeting s receptors may prevent cognitive impairments produced by methamphetamine. In the present study, an optimized s receptor antagonist, AZ66, was
evaluated against methamphetamine-induced neurotoxicity and cognitive dysfunction. AZ66 was found to be
highly selective for s receptors compared to 64 other sites tested. Pretreatment of male, Swiss Webster mice with
i.p. dosing of AZ66 signiﬁcantly attenuated methamphetamine-induced striatal dopamine depletions, striatal
dopamine transporter reductions and hyperthermia. Additionally, neurotoxic dosing with methamphetamine
caused signiﬁcant memory impairment in the object recognition test, which was attenuated when animals were
pretreated with AZ66 ; similar trends were observed in the step-through passive avoidance test. Taken together,
these results suggest that targeting s receptors may provide neuroprotection against the neurotoxicity and
cognitive impairments produced by methamphetamine.
Received 21 April 2012 ; Reviewed 13 June 2012 ; Revised 2 July 2012 ; Accepted 3 July 2012 ;
First published online 29 August 2012
Key words : Aopamine, memory, methamphetamine, neurotoxicity, s receptors.

Introduction
Methamphetamine is an addictive psychostimulant
and currently listed as the second most abused illicit
substance in the world (United Nations, 2007).
Methamphetamine abuse can result in several negative
consequences, including signiﬁcant neurotoxicity at high
or repeated doses (Cadet & Krasnova, 2009 ; Kita et al.
2003). Chronic use results in long-lasting nerve terminal
degeneration in speciﬁc regions of the brain (Cadet &
Krasnova, 2009). Methamphetamine is believed to exert
these eﬀects through its interaction with monoamine
transporters, primarily in the dopaminergic system
(Krasnova & Cadet, 2009 ; Schep et al. 2010 ; Sora et al.
2009). This results in the release of dopamine from
Address for correspondence : Dr R. R. Matsumoto, West Virginia
University, School of Pharmacy, P. O. Box 9500, Morgantown, WV 26506,
USA.
Tel. : 1 304 293 1450 Fax : 1 304 293 2576
Email : rmatsumoto@hsc.wvu.edu

synaptic vesicles within the nerve terminal and a
resulting release of excess dopamine into the synapse by
inhibition of reuptake and reversal of ﬂow through
dopamine transporters (DATs ; Krasnova & Cadet, 2009 ;
Schep et al. 2010). This is believed to lead to nerve terminal degeneration through the formation of reactive
oxygen species and reactive nitrogen species (Kita et al.
2003).
The neurotoxic eﬀects of methamphetamine appear
to have signiﬁcant clinical implications, as neurological
deﬁcits have been found in human clinical populations of
chronic methamphetamine abusers (McCann et al. 1998 ;
Schep et al. 2010 ; Volkow et al. 2001a, b ; Wilson et al. 1996).
In addition, it has been documented that signiﬁcant and
long-lasting nerve terminal degeneration can occur in
these patients (McCann et al. 1998 ; Wilson et al. 1996),
potentially resulting in cognitive impairments (Hart
et al. 2012). The role of methamphetamine abuse in cognitive-related decline has remained controversial. However, current studies suggest that, while acute use of
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evaluate a selective s receptor antagonist for its ability to
attenuate cognitive impairment following repeated methamphetamine administration.
Method
Receptor binding studies
To evaluate the overall selectivity of AZ66 for s receptors,
the compound was subject to NOVAScreen (Caliper
Life Sciences, USA) at targets not previously reported
(Seminerio et al. 2012). Further details of each assay
condition can be accessed through their website (www.
caliperls.com).
Animals
Male, Swiss Webster mice (21–30 g ; Harlan, USA) were
used for all experiments. Animals were housed 1–5 per
cage with a 12:12 h light/dark cycle (lights on 06:00
hours) and ad libitum food and water. They were allowed
1 wk to acclimatize following their arrival before being
used in an experiment. All procedures were approved by
the Institutional Animal Care and Use Committee at West
Virginia University.
Drugs and treatment
(+)-Methamphetamine hydrochloride was purchased
from Sigma-Aldrich (USA) and sterile saline solution was
purchased from Teknova (USA). The s receptor antagonist, AZ66, was synthesized as previously described
(Seminerio et al. 2012). All drug solutions were made with
saline and the solution volumes were administered relative to body weight (0.1 ml/10 g).
Mice were randomly divided into groups that were
injected with saline (0.1 ml/10 g i.p.) or AZ66 (10 mg/kg
i.p.) 15 min prior to injection with saline or methamphetamine (5 mg/kg i.p.). The dose of AZ66 was chosen
based on previous studies, which demonstrated signiﬁcant eﬀects against methamphetamine while exerting no
eﬀects on its own (Seminerio et al. 2012). Similarly, previous work in our lab has shown neurotoxic dosing with
methamphetamine produces a dose-dependent depletion
of dopamine levels in the mouse striatum, with 5 mg/kg
being the lowest dose producing statistically signiﬁcant
eﬀects (Kaushal et al. 2011). Therefore, 10 mg/kg AZ66
and 5 mg/kg methamphetamine were used.
Each group of mice received their treatment a total of
four times at 2 h intervals. One hour after each treatment,
the body temperatures of the mice were recorded. To
allow suﬃcient time for the methamphetamine-induced
degeneration of nerve terminals to occur, the animals
were killed and the brains removed 1 wk later (Cappon
et al. 2000). The striata of the mice were then collected
on ice and evaluated for dopamine levels and DAT expression. The detailed procedure for each of the endpoints is provided below.
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methamphetamine may actually improve memory and
attention, chronic use results in decreases in memory and
reaction speed (Hart et al. 2012). Methamphetamineinduced cognitive impairment has been observed both
in humans via clinical tests such as the Wisconsin Card
Sorting Test and animal studies, which evaluate maze
sequential learning (Chapman et al. 2001), motor performance (Walsh & Wagner, 1992), spatial impairment
(Friedman et al. 1998) and object recognition (Belcher et al.
2008 ; Bisagno et al. 2002 ; Kamei et al. 2006 ; O’Dell et al.
2011 ; Reichel et al. 2012). It is hypothesized that methamphetamine use may increase an abuser’s risk of
neurodegenerative diseases such as Parkinson’s disease
(Callaghan et al. 2010 ; Kuehn, 2011 ; Morrow et al. 2011).
While these cognitive eﬀects of methamphetamine have
primarily been studied in the hippocampal regions of the
brain, recent evidence has shown that the striatum plays
an important role in memory (Sadeh et al. 2011) and
striatal dopaminergic deﬁcits are evident in patients with
Parkinson’s disease (Altgassen et al. 2007 ; Beste et al.
2009).
Previous work has demonstrated that sigma (s) receptors may be a viable target to attenuate some of
the eﬀects of methamphetamine. Methamphetamine interacts with both s1 and s2 receptors at physiologically
relevant concentrations (2¡0.3 and 47¡10 mM, respectively ; Nguyen et al. 2005) and s receptors have been
shown to be involved in many of the behavioural and
physiological eﬀects of methamphetamine (Kaushal &
Matsumoto, 2011 ; Kaushal et al. 2011, 2012 ; Matsumoto
et al. 2008 ; Seminerio et al. 2011, 2012). Pretreatment
with selective s1/s2 receptor antagonists such as AC927
(N-phenethylpiperdine oxalate) or CM156 (3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[D]thiazole-2(3H)-thione)
have been shown to attenuate methamphetamineinduced hyperthermia, dopaminergic neurotoxicity and
serotonergic neurotoxicity, in addition to mitigating
some of the stimulant eﬀects of methamphetamine, such
as increases in locomotor activity (Kaushal et al. 2011 ;
Matsumoto et al. 2008). Other reports have shown that
activation of s receptors can provide anti-amnesic and
neuroprotective eﬀects in various models of cognitive
dysfunction (van Waarde et al. 2011) and s receptors are
thought to have a functional role in Parkinson’s disease
(Mishina et al. 2005).
The current study utilized AZ66 (3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-ﬂourobenzo[D]thiazol-2(3H)one), a mixed s1/s2 antagonist derived from CM156 and
optimized for metabolic stability (Seminerio et al. 2011), to
determine its eﬀects as a pretreatment against methamphetamine-induced hyperthermia, striatal dopaminergic
neurotoxicity and cognitive dysfunction. AZ66 has previously been shown to mitigate many of the behavioural
eﬀects of methamphetamine, including the development
and expression of behavioural sensitization (Seminerio
et al. 2012), suggesting its potential importance toward
future drug development studies. This study is the ﬁrst to

AZ66 blocks methamphetamine eﬀects
Dopamine assays

Laboratories, USA). Sections were then incubated with
biotinylated secondary anti-rat antisera (ab6844, dilution
1 : 200 ; Abcam, USA) in TBS for 60 min. This was then
followed by incubation of the sections with avidinbiotinylated peroxidase substrate in TBS for 60 min. The
staining was then visualized by reacting 3,3k-diaminobendine containing 0.01 % H2O2 for 5 min.
The stained sections were mounted onto gelatinecoated slides and dried. The sections were then dehydrated, cleared and coverslipped. The images were
captured digitally using a Zeiss Axiovert 40 microscope
(Carl Zeiss Microscopy, USA) and optical density readings were quantiﬁed in anterior regions of the striatum
using ImageJ software (National Institutes of Health,
USA). To obtain the data point for a given animal, at least
two sections per mouse brain were processed and the
optical density readings from the striatal region of each
section were averaged.
Body temperature
Mice (n=6–8/group) were randomly assigned to treatment groups, which were the same as those described for
the dopamine assays. All of the combinations of drug
treatments were given i.p. at 2 h intervals a total of four
times. Core body temperature was measured 1 h following each of the treatment combinations with a Thermalert
TH-S monitor (Physitemp Instruments Inc., USA).
During the temperature measurements, mice were gently
held at the base of the tail and a probe (RET-3) was inserted approximately 2.5 cm past the rectum into the colon for 8–10 s until a rectal temperature was maintained
for 3–4 s.

DAT immunohistochemistry
Striatal sections were assessed for DAT expression.
Mice (n=4/group) were randomly assigned to one
of the following treatment groups : (1) saline+saline ;
(2) saline+methamphetamine (5 mg/kg i.p.) ; (3) AZ66
(10 mg/kg i.p.)+methamphetamine (5 mg/kg i.p.) ;
(4) AZ66 (10 mg/kg i.p.)+saline. The mice received their
treatments at 2 h intervals, a total of four times. One week
following treatment, the mice were perfused transcardially with 0.1 M phosphate buﬀered saline (pH 7.4), followed by 4 % paraformaldehyde. The brains were further
ﬁxed overnight in 4 % paraformaldehyde. Coronal sections (50 mm) of the ﬁxed tissue were made throughout
the rostral-caudal extent of the striatum using a cryostat
and processed in a free-ﬂoating state in 0.1 M Tris-HCl
buﬀered saline (TBS, pH 7.5). The sections were treated
with 0.3 % H2O2 in TBS for 30 min at room temperature.
The sections were then treated with TBS containing 0.2 %
Triton X-100 and 1.5 % normal goat serum for 30 min at
room temperature. Incubation of the sections with rat
anti-mouse DAT antibody (MAB369, dilution 1 : 10 000 ;
Chemicon International, USA) was performed for 36 h at
4 xC. The labelled sections were then washed twice in
TBS and processed using Vectastain Elite ABC (Vector

Memory measurements
Mice (n=10/group) were randomly assigned to treatment groups, which were the same as those described for
the neurotoxicity studies. All of the combinations of drug
treatments were given i.p. at 2 h intervals a total of four
times. Following 1 wk, animals were evaluated for
memory in the object recognition test and step-through
passive avoidance test. The detailed procedure for each of
the tests is provided below.
Object recognition test
The test was carried out as described previously (Li et al.
2011). Each mouse was allowed to move freely in an
open-ﬁeld box for 5 min as habituation. Twenty-four
hours later, mice were individually placed in the centre
of the box containing two identical objects (Lego blocks)
located in the two diagonal corners. The cumulative time
spent exploring each object was recorded during a 5 min
period. Exploration was deﬁned as actively touching or
facing (within 2 cm toward) the object. One day later
(24 h after training), mice were tested for memory using
the same procedure except that one of the familiar objects
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Mice (n=6–8/group) were randomly assigned to one of
the following treatments : (1) saline+saline ; (2) saline+
methamphetamine (5 mg/kg i.p.) ; (3) AZ66 (10 mg/kg
i.p.)+saline ; (4) AZ66 (10 mg/kg i.p.)+methamphetamine (5 mg/kg i.p.). The mice received their designated
treatments a total of four times at 2 h intervals. One week
later, the striatum was dissected from the mice and then
frozen in liquid nitrogen. The tissues were stored at
x80 xC for later analysis of dopamine content.
Using a dopamine research enzyme immunoassay kit
and protocols provided by the manufacturer (Rocky
Mountain Diagnostics, USA), mouse brain striatal dopamine was quantiﬁed. Brain tissues were homogenized in
0.01 N HCl. Dopamine was extracted and then acylated
to N-acyldopamine using the buﬀer and reagents provided by the enzyme-linked immunosorbent assay
(ELISA) kit. Acylated dopamine from the tissue samples
was then incubated with solid phase bound dopamine,
dopamine antiserum and antiserum buﬀer to compete for
a ﬁxed number of antiserum binding sites. Free antigen
and free antigen-antiserum complexes were removed
via the wash buﬀer. The antibody bound to the solid
phase dopamine was detected using an anti-rabbit IgGperoxidase conjugate with 3,3k,5,5k-tetramethylbenzidine
as the substrate. The amount of antibody bound to the
solid phase dopamine was measured by monitoring
the reaction at 450 nm. The solid phase dopamine
measured was inversely proportional to the dopamine
concentration of the tissue sample and was quantiﬁed
relative to a standard curve of known concentrations.
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was replaced with a novel object. The time of exploration
of each object [Tf and Tn for familiar (f) and novel (n)
objects, respectively] was recorded for determination of
the recognition index (RI)=Tn/(Tf+Tn).
Step-through passive avoidance test

Data analysis
The data from the dopamine assays, immunohistochemical studies, core body temperature readings,
object recognition test and step through passive avoidance test were evaluated using one-way analysis of
variance (ANOVA). Post-hoc analyses were performed
with Tukey’s tests for pairwise comparisons. For all
analyses, p<0.05 was considered statistically signiﬁcant.
GraphPad Prism (USA) was used for all data analyses.
Results
Radioligand binding assays
Table 1 summarizes the aﬃnities of AZ66 for radioligand
binding sites. Previous reports showed that AZ66 had
high aﬃnity for both s1 and s2 receptors in the nanomolar
and subnanomolar range (Seminerio et al. 2012).
Compared to its high aﬃnity for s receptors, AZ66 displayed a >100-fold preference relative to all 64 non-s
binding sites tested.

Dopamine assays
Figure 1 shows the eﬀects of the s receptor antagonist
AZ66 on methamphetamine-induced dopamine depletions in the mouse striatum. ANOVA conﬁrmed signiﬁcant diﬀerences between groups (F3,36=13.67, p<0.001).
Post-hoc Tukey’s tests conﬁrmed that methamphetamine
produced signiﬁcant decreases in striatal dopamine
levels compared to saline-treated animals (q=6.17,
p<0.001) and pretreatment with AZ66 signiﬁcantly attenuated methamphetamine-induced dopamine depletions
(q=8.88, p<0.001). When AZ66 was administered alone,
the striatal dopamine levels were not signiﬁcantly changed compared to saline-treated animals (p>0.05).
DAT immunohistochemistry
To test the eﬀects of AZ66 on methamphetamine-induced
DAT reductions, immunohistochemical analyses were
conducted. Figure 2 depicts the eﬀects of methamphetamine and AZ66 on DAT immunoreactivity in the mouse
striatum, with a signiﬁcant diﬀerence between the treatment groups (F3,88=118.70, p<0.0001). Post-hoc Tukey’s
multiple comparisons test conﬁrmed that methamphetamine caused a signiﬁcant reduction in DAT immunoreactivity relative to treatment with saline alone
(q=25.55, p<0.001). Pretreatment with AZ66 signiﬁcantly attenuated methamphetamine-induced neurotoxicity (q=20.97, p<0.001), whereas treatment with AZ66
alone had no signiﬁcant eﬀects on DAT expression compared to saline alone (q=3.65, p>0.05).
Hyperthermia
Methamphetamine produced a signiﬁcant increase in
body temperature, which was attenuated by AZ66. Oneway ANOVA showed signiﬁcant diﬀerences between all
groups (F3,15=19.08, p<0.001). ANOVA of body temperature measured following each treatment time-point
revealed signiﬁcant changes in all but the ﬁrst-time point
(BT1) (Fig. 3) : BT1 (F3, 39=9.67, p>0.05) ; BT2 (F3, 39=
13.93, p<0.01) ; BT3 (F3, 39=14.02, p<0.01) ; BT4 (F3, 39=
21.14, p<0.01). Post-hoc Tukey’s tests conﬁrmed that
methamphetamine signiﬁcantly increased body temperature after the second injection onwards (BT2, q=8.09,
p<0.001 ; BT3, q=7.72, p<0.001 ; BT4, q=8.36, p<0.001).
AZ66 signiﬁcantly mitigated the hyperthermic eﬀects of
methamphetamine (BT3, q=5.20, p<0.01 ; BT4, q=5.11,
p<0.01). When AZ66 was administered in the absence of
methamphetamine, ANOVA showed that there were no
signiﬁcant changes in basal body temperature compared
to saline-treated animals (q=1.56, p>0.05).
Memory measurements
Object recognition
The eﬀects of methamphetamine and AZ66 on recognition memory were evaluated in Fig. 4. ANOVA showed
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The test was performed as described previously (Zhang
et al. 2005) with some modiﬁcations. The apparatus
(Model E10–16SC ; Coulbourn Instruments, USA)
consisted of a two-compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door. The experiment consisted
of single training and testing sessions.
On the ﬁrst day, the animal was placed in the chamber
and allowed to roam freely between the illuminated and
darkened side for 5 min. During training (24 h later), the
mouse was placed in the illuminated compartment,
facing away from the closed guillotine door, for 1 min
before the door was raised. The latency to enter the darkened compartment was recorded. After the mouse entered the darkened compartment, the door was closed
and an electric shock (0.4 mA, 5 s) was delivered from the
steel-rod ﬂoor. This was repeated until the latency for the
animal to enter the dark compartment exceeded 60 s once
the door was open. The number of shocks the animal received before meeting the >60 s criterion was also recorded.
Twenty-four hours later, mice began the testing session. To begin the test, the mouse was again placed in the
illuminated compartment, with the guillotine door closed
for 1 min. After 1 min, the door was opened and the retention latency to enter the darkened compartment was
recorded for up to 300 s, at which time the test was terminated. No shocks were delivered to mice that entered
the darkened compartment during the test trial.

Neurotoxicity evaluations

AZ66 blocks methamphetamine eﬀects
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Table 1. Binding aﬃnities of AZ66
Radioligand

Non-speciﬁc binding

Tissue or cell

Ki

5 nM [3H](+)-pentazocine
3 nM [3H]di-o-tolylguanidine

10 mM haloperidol
10 mM haloperidol

Rat brain
Rat brain

2.4¡0.63
0.51¡0.15

4.0 nM [3H]NECA
0.3 nM [3H]7-MeOxy-Prazosin
1 nM [3H]Rx 821002
0.04 nM [125I](-) iodocyanopindolol
0.5 nM [3H]CP 55940

1 mM NECA
1 mM phentolamine mesylate
1 mM phentolamine mesylate
3 mM alprenolol
1 mM HU-210

>10 000
>100
>100
>10 000
>10 000

Cannabinoid, CB2

0.5 nM [3H]CP 55940

1 mM HU-210

Dopamine D4.2

0.15 nM [3H]spiperone

1 mM haloperidol

GABA A, agonist site
GABA A, BDZ a 1
GABA-B
Glutamate, AMPA
Glutamate, kainate
Glutamate, NMDA agonist
Glutamate, NMDA glycine
Glutamate, NMDA/PCP
Glutamate, mGluR1
Glutamate, mGluR5
Glycine, strychnine
Histamine H1
Histamine H2
Histamine H3
Muscarinic, central
Muscarinic, peripheral
Muscarinic M1

5 nM [3H]GABA
1 nM [3H]ﬂunitrazepam
1 nM [3H]CGP 54626A
5 nM [3H]AMPA
10 nM [3H]kainic acid
2 nM [3H]CGP 39653
4 nM [3H]MDL-105,519
10 nM [3H]TCP
5 nM [3H]TCP
20 nM [3H]quisqualic acid
10 nM [3H]MPEP
16 nM [3H]strychnine
2 nM [3H]pyrilamine
0.1 nM [125I]aminopotentidine
0.2 nM [3H]N-a-MeHistamine
0.15 nM [3H]QNB
0.3 nM [3H]QNB
0.5 nM [3H]N-methyl scopolamine

1 mM GABA
0.5 mM ﬂumazenil
100 mM baclofen
100 mM AMPA
10 mM kainic acid
300 mM NMDA
3 mm MDL-105,519
100 mM (+)-MK801
10 mM cyclazocine
1 mM L-glutamate
10 mM MPEP
100 mM strychnine nitrate
10 mM triprolidine
3 mM tiotidine
100 nM R(-)a-methylhistamine
0.1 mM atropine
0.1 mM atropine
1 mM (x)scopolamine

Muscarinic M2

0.5 nM [3H]N-methyl scopolamine

1 mM methylscopolamine

Nicotinic, muscle
Nicotinic, neuronal
Opioid, k 1
Opioid, m
Angiotensin II, AT1
Angiotensin II, AT2
Bradykinin, BK2
CCK1
CCK2
CRF, non-selective
Endothelin, ETA
Endothelin, ETB
Oestrogen
Galanin, non-selective
Glucocorticoid
Neurokinin, NK1
Neurokinin, NK2 (NKA)

1 nM [125I]a-bungarotoxin
0.05 nM [3H]epibatidine
0.75 nM [3H]U-69593
1 nM [3H]DAMGO
0.06 nM [125I](Sar1-Ile8)angiotensin
0.1 nM [125I]Tyr4-angiotensin II
0.2 nM [3H]bradykinin
0.02 nM [125I]CCK-8
0.02 nM [125I]CCK-8
0.1 nM [125I]Tyr0-oCRF
0.033 nM [125I]endothelin-1
0.025 nM [125I]endothelin-1
0.1 nM [125I]3,7b-oestradiol
0.07 nM [125I]galanin
1 nM [3H]dexamethasone
1.4 nM [3H]substance P
0.1 nM [125I]neurokinin A

10 mM nicotine
20 nM epibatidine
1 mM U-69593
1 mM naloxone
1 mM angiotensin II
0.05 mM angiotensin II
100 nM bradykinin TFA
1 mM CCK-8
1 mM CCK-8
1 mM Tyr0-oCRF
0.1 mM endothelin-1
0.1 mM endothelin-1
10 nM 17b-oestradiol
100 nM galanin (porcine)
10 mM triamcinolone
1 mM substance P
1 mM neurokinin A

Neurokinin, NK3 (NKB)
Oxytocin
Testosterone, cytosolic
TRH
VIP, non-selective
Vasopressin 1

0.1 nM [125I]eledoisin
1 nM [3H]oxytocin
0.5 nM [3H]methyltrienolone
2 nM [3H](3MeHis2)TRH
0.05 nM [125I]VIP
0.5 nM [3H]phenylalanyl- 3,4,5-v

1 mM eledoisin
1 mM oxytocin
0.7 mM methyltrienolone
10 mM TRH
1 mM VIP
1 mM Arg8-vasopressin

Bovine striatum
Rat forebrain
Rat cortex
Human neuroepithelioma
Human recombinant
HEK293 cells
Human recombinant
CHO cells
Human recombinant
CHO cells
Bovine cerebellum
Bovine cortex
Rat cerebral cortex
Rat forebrain
Rat forebrain
Rat forebrain
Rat cortex/hippocampus
Rat forebrain
Rat brain
Rat cerebellum
Rat brain
Rat spinal cord
Bovine cerebellum
Guinea pig striatum
Rat forebrain
Rat cerebral cortex
Guinea pig bladder
Human recombinant
CHO cells
Human recombinant
CHO cells
Human TE671 cells
Human SK-N-F1 cells
Guinea pig cerebellum
Rat forebrain
Human KAN-TS cells
Bovine cerebellum
Guinea pig ileum
Mouse pancreas
Mouse forebrain
Rat cerebral cortex
Human neuroblastoma
Human astrocytoma
Human breast cancer
Rat brain
Human recombinant
Rat submaxillary gland
Human recombinan
CHO cells
Rat cerebral cortex
Rat uterus
Human LnCAP cells
Rat forebrain
Rat forebrain
Rat liver

>10 000
>100
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>100
>100
>100
>100
>100
>100
>100
>10 000
>10 000
>100
>100
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
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Sigma (s) receptors
s1
s2
Neurotransmitter related
Adenosine
Adrenergic, a1
Adrenergic, a2
Adrenergic, b1
Cannabinoid, CB1
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Table 1 (cont.)
Non-speciﬁc binding

Tissue or cell

Ki

5 nM [3H]diltiazem, cis(+)

10 mM diltiazem

Rat cerebral cortex

>100

0.2 nM [3H]nitrendipine

1 mM nifedipine

Rat cerebral cortex

>10 000

0.01 nM [125I]v-conotoxin GVIA
0.2 nM [3H]glibenclamide
0.05 nM [125I]apamin
2 nM [3H]batrachotoxin

0.1 mM v-conotoxin GVIA
0.1 mM glibenclamide
100 nM apamin
1 mM aconitine

Rat cerebral cortex
Rat cerebral cortex
Rat forebrain
Rat forbrain

>10 000
>10 000
>10 000
>100

100 mM physostigmine
0.1 mM Ro 41-1049
100 mM aminooxy acetic acid
500 nM leukotriene B4
1 mM leukotriene D4
1 mM Ro 41-1049
10 mM Ro 16-6491
100 mM NOARG

Human recombinant
Rat cerebral cortex
Rat striatum
Guinea pig spleen
Guinea pig lung
Rat liver mitochondria
Rat liver mitochondria
Rat brain

>100
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000
>10 000

1 mM C16-PAF
10 mM pinane-thromboxane

Rabbit platelets
Human platelets

>10 000
>10 000

Enzymes and other miscellaneous
Acetylcholine esterase
0.3 mM [3H]acethylthiocholine
Choline acetyltransferase
0.2 nM [14C]acetyl coenzyme
Glutamic acid decarboxylase 4 mM [14C]L-glutamic acid
0.48 nM [3H]leukotriene B4
Leukotriene, LTB4 (BLT)
Leukotriene, LTD4 (CysLT1) 0.2 nM [3H]leukotriene D4
MAOA oxidase, peripheral
50 mM [14C]5-HT
MAOB oxidase, peripheral
10 mM [14C]phenylethylamine
Nitric oxide, NOS
5 nM [3H]NOARG
(neuronal binding)
Platelet activating factor
1.7 nM [3H]hexadecyl-acetyl-PAF
2 nM [3H]SQ 29,548
Thromboxane, TXA2

GABA, c-aminobutyric acid ; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid ; NMDA, N-methyl-D-aspartate ;
PCP, phencyclidine ; Ro 41,1049, N-(2-aminoethyl)-5-(3-ﬂuorophenyl)-4-thiazolecarboxamide ; Ro 16-6491, N-(2-aminoethyl)4-chlorobenzamide ; CCK, cholecystokinin ; CRF, corticotrophin releasing factor ; TRH, thyrotropin releasing hormone ;
VIP, vasoactive intestinal peptide ; NECA, 5k-N-ethylcarboxamidoadenosine ; Rx 821002, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin2-yl)-4,5-dihydro-1H-imidazole ; CP 55,940, 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol ;
HU-210, (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol ;
MAO, monoamine oxidase ; CGP 54626A, cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2hydroxypropyl]phosphinic acid ; CGP 39653, 2-amino-4-propyl-5-phosphono-3-pentenoic acid ; MDL-105,519,
(E)-4,6-dichloro-3-(2-phenyl-2-carboxyethenyl)indole-2-carboxylic acid ; MK801, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate dizocilpine hydrogen maleate ; TCP,1-(1-(2-thienyl)cyclohexyl)piperidine ;
MPEP, 2-methyl-6-(phenylethynyl)pyridine ; U-69593, (+)-(5a,7a,8b)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide ; TFA, triﬂuoroacetic acid ; QNB, quinuclidinyl benzilate ; DAMGO, (2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ; GVIA,
(3-iodotyrosyl22)v-conotoxic ; 5-HT, serotonin ; NOARG, L-NG-nitro-arginine ; PAF, platelet activating factor ; SQ 29,548,
[1S-[1a, 2a(Z),3a,4a]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid ; Aﬃnities
(Ki in nanomolar, mean¡S.E.M.) were determined in tissue or cell homogenates. Values of >100 and >10 000 signify that there was
<50 % displacement of the radioligand at that concentration.

signiﬁcant diﬀerences between the groups in the object
recognition test (F3,31=9.01, p<0.001). Post-hoc Tukey’s
tests conﬁrmed that methamphetamine produced signiﬁcant impairment of recognition memory when compared to the saline control (q=7.04, p<0.001) ; this was
prevented by pretreatment with AZ66 (q=5.31, p<0.01).
Animals treated with AZ66 alone showed no signiﬁcant
diﬀerence from saline-treated animals (q=2.50, p>0.05).

the dark compartment during testing (Fig. 5b) among any
of the groups tested (F3,31=1.03, p>0.05). However, while
not signiﬁcant, these results demonstrate a similar trend
to that seen with the object recognition, in which animals
treated with methamphetamine alone showed increased
entries into the dark compartment during the testing
period and decreased latency during the testing period.
These tendencies were reduced by pretreatment with
AZ66.

Step-through passive avoidance test
Figure 5 depicts the eﬀects of methamphetamine and
AZ66 on memory using the step-through passive avoidance test. No signiﬁcant eﬀects were observed on the %
entries required for acquisition of the passive avoidance
task during training (Fig. 5a) and the 24 h latency to enter

Discussion
The selective s receptor antagonist, AZ66, has been
optimized for metabolic stability and tested against
the stimulant eﬀects of methamphetamine in our previous study (Seminerio et al. 2012). The current study
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Fig. 1. Eﬀects of methamphetamine (Meth) and AZ66 on
dopamine (DA) levels in the mouse striatum. Mice were
pretreated with saline (0 mg/kg i.p. AZ66) or AZ66 (10 mg/kg
i.p.). After 15 min, the mice were then treated with saline
(xMeth) or Meth (+Meth, 5 mg/kg i.p.). This treatment
schedule was repeated four times at 2 h intervals. One week
later, the brain was removed and DA levels were measured
using enzyme-linked immunosorbent assay. Data are reported
as mean¡S.E.M. *** p<0.001 vs. saline, ## p<0.001 vs. Meth ;
n=6–8 per group.

demonstrates that AZ66 has protective eﬀects against
methamphetamine-induced dopaminergic neurotoxicity,
hyperthermia and memory impairment. These ﬁndings
are important as AZ66 retained its protective pharmacological proﬁle and high selectivity for s receptors, following optimization from its parent compound CM156,
deeming it credible as a lead compound for future drug
development.
Consistent with prior studies (Kaushal & Matsumoto,
2011), this work also demonstrates that targeting s receptors can provide neuroprotective eﬀects. While future
studies will need to be conducted to delineate the exact
mechanism of this interaction, a number of hypotheses
can begin to explain the neuroprotective eﬀects of s receptor antagonists. Sigma receptors have been shown to
modulate various neurotransmitter systems aﬄicted by
methamphetamine (Bastianetto et al. 1995 ; Guitart et al.
2004 ; Mishina et al. 2005). Speciﬁcally, our results further
emphasize a modulatory role of s receptors in the dopaminergic system and regions of the brain responsible for
dopamine transmission.
Dopamine depletions following methamphetamine
administration appear primarily dependent on DAT
function (Cadet & Krasnova, 2009 ; Krasnova & Cadet,
2009 ; Pu et al. 1994 ; Schmidt et al. 1985). Animals lacking
DATs are protected against dopamine depletions
(Fumagalli et al. 1998 ; Giros et al. 1996). In addition,
striatal dopamine depletions are proportional to the degree of hyperthermia, which is linked to methamphetamine-induced lethality (Bowyer et al. 1994). The selective
s receptor antagonist, AZ66, was found to protect against
methamphetamine-induced striatal dopamine and DAT
reductions as well as increases in body temperature.
These neuroprotective properties of AZ66 are likely due
to its ability to modulate body temperature following

methamphetamine exposure. Previous work has demonstrated that hypothermia can provide neuroprotection
against methamphetamine-induced dopamine deﬁcits
(Bowyer et al. 1994). In addition, earlier studies in our lab
have shown a strong correlation between the ability of s
receptor ligands to mitigate methamphetamine-induced
hyperthermia and dopamingeric neurotoxicity (Kaushal
et al. 2011). These ﬁndings support previous studies that
also demonstrate neuroprotective properties of s receptor
antagonists against methamphetamine (Kaushal et al.
2011 ; Matsumoto et al. 2008 ; Seminerio et al. 2011).
With evidence linking methamphetamine exposure to
an increased risk for the development of Parkinson’s
disease, dopaminergic neurotoxicity remains a central
theme. A myriad of studies have shown that methamphetamine produces signiﬁcant depletions of dopamine
levels and DATs in both humans and animal models
(Cadet & Krasnova, 2009 ; Kita et al. 2003 ; Morrow et al.
2011 ; Schmidt et al. 1985 ; Volkow et al. 2001a, b ; Wilson et
al. 1996). Furthermore, striatal neurotoxicity, which is the
focus of this study, has been implicated in Parkinson’s
disease and can impact cognitive function (Altgassen et
al. 2007 ; Beste et al. 2009 ; Callaghan et al. 2010).
While the majority of research has been dedicated to
the acute eﬀects of methamphetamine on cognitive function (some showing an increase in cognitive function
following low to moderate doses ; Hart et al. 2012), less
is known regarding the long-term eﬀects of repeated
methamphetamine abuse on cognition. The following
paragraphs will discuss the relationship between repeated methamphetamine administration and its eﬀects
on the dopaminergic system and cognitive functioning.
In addition, the functional importance of targeting s receptors to prevent methamphetamine-induced cognitive
impairments will also be discussed.
A number of neurotransmitter systems are likely involved in methamphetamine-induced memory impairment, including dopamine (Gough et al. 2002 ; Han & Gu,
2006 ; Kuczenski et al. 1995). Dopamine has been shown to
modulate diﬀerent cognitive functions, including memory, attention, task switching and response inhibition
(Cohen & Servan-Schreiber, 1993 ; Nordahl et al. 2003).
Dopamine deﬁcits in the striatum have been shown to
reduce reaction time and simple task performance
(Baunez & Robbins, 1999 ; Nordahl et al. 2003) while dopamine deﬁcits in the prefrontal cortex also contribute to
cognitive dysfunction (Baunez & Robbins, 1999 ; Roberts
et al. 1994 ; Rogers et al. 1999). Methamphetamine is
known to produce eﬀects in both the striatum and prefrontal cortex (Cadet & Krasnova, 2009 ; Kita et al. 2003),
in which s receptors are expressed (Guitart et al. 2004 ;
Hayashi et al. 2010). In addition, s receptors are thought
to modulate the dopaminergic system (Bastianetto et al.
1995). The s receptor ligands, SA 4503 and AC927, have
both been recently reported to modulate methamphetamine-induced dopamine release (Kaushal et al. 2012 ;
Rodvelt et al. 2011), suggesting a role for s receptors in the
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Fig. 2. Eﬀects of methamphetamine (Meth) and AZ66 (AZ) on dopamine transporter (DAT) immunoreactivity in the mouse
striatum. Mice were pretreated with saline (Sal) or AZ (10 mg/kg i.p.). After 15 min, the mice were then treated with Sal or Meth
(5 mg/kg i.p.). This treatment schedule was repeated four times at 2 h intervals. One week later, the brains were removed and
stained for DAT immunoreactivity. A representative section from each treatment group is shown, together with average optical
density readings (mean¡S.E.M.). *** p<0.001 vs. saline, ### p<0001 vs. Meth ; n=4 per group.
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Fig. 3. Eﬀects of AZ66 on methamphetamine (Meth)-induced
hyperthermia. Mice were pretreated with saline or AZ66
(10 mg/kg i.p.) and after 15 min the mice were treated with
saline or Meth (5 mg/kg i.p.). Core body temperature was
measured 1 h after each injection combination. This regimen was
repeated four times at 2 h intervals. Data are reported as
mean¡S.E.M. *** p<0.001 vs. saline, ## p<0.01 vs. Meth ; n=6–8
per group.

dopaminergic eﬀects of methamphetamine. In addition,
other s receptor ligands including CM156, SN79 and
AC927, have all been shown to prevent striatal DAT reductions following methamphetamine exposure while
having no signiﬁcant eﬀect on striatal DAT expression on
its own (Kaushal et al. 2011 ; Matsumoto et al. 2008).
The striatum plays an important though often forgotten role in cognition. It has been shown that the striatum

cooperates with the hippocampus in the formation of
episodic memories (Sadeh et al. 2011), which are often
impaired in patients with Parkinson’s disease, and subsequent dopaminergic striatal deﬁciencies (Altgassen et al.
2007 ; Beste et al. 2009). Dopamine plays a strong role in
the formation of episodic memories similar to those seen
in the object recognition test (Hotte et al. 2005). Therefore,
it should come as no surprise that neurotoxic doses
of methamphetamine, which signiﬁcantly lower striatal
dopamine levels, impair object recognition memory
(Belcher et al. 2008 ; Bisagno et al. 2002 ; O’Dell et al. 2011 ;
Reichel et al. 2012 ; Schroder et al. 2003). In the present
study, pretreatment with AZ66 signiﬁcantly attenuated
the amnesic eﬀect of neurotoxic methamphetamine in
object recognition, which appears mediated at least in
part through s receptors, as pretreatment with AZ66
also attenuated methamphetamine-induced dopaminergic neurotoxicity in the striatum. It is also possible that
protection of these necessary striatal dopamine stores
resulted in enhanced object recognition memory via an
indirect modulatory role on glutamatergic transmission,
given that striatal dopamine plays a role in modulating
glutamatergic signalling (Marti et al. 2002 ; Yamamoto &
Davy, 1992), which is important in mediating object recognition memory (Roullet et al. 2001 ; Sargolini et al. 2003)
and s receptors can regulate glutamatergic transmission
by functionally modulating the NMDA receptor complex
(Guitart et al. 2004).
The pharmacology and neuroanatomy of object recognition memory is very complex and can rely upon many
brain regions and neurotransmitters. However, recent
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Fig. 4. Eﬀects of AZ66 (AZ) on methamphetamine (Meth)induced memory impairment in the object recognition test. Mice
were pretreated with saline (Sal) or AZ (10 mg/kg i.p.). After
15 min, the mice were then treated with Sal or Meth (5 mg/kg
i.p.). This treatment schedule was repeated four times at 2 h
intervals. One week later, the animals underwent the object
recognition test. RI, Recognition Index. Data are reported as
mean¡S.E.M. *** p<0.001 vs. Sal ; ## p<0.01 vs. Meth ; n=10
per group.

research has implicated the perirhinal cortex as an important brain region responsible for object recognition
memory (Reichel et al. 2012 ; Wan et al. 1999 ; Warburton &
Brown, 2010). While projections between the prefrontal
cortex and hippocampus are thought to contribute to
cognitive memory formation (Hirai et al. 2012 ; Miyashita
& Chang, 1988), the prefrontal cortex does not directly
project to the hippocampus, but rather to the perirhinal
cortex and amygdala (Burwell, 2001 ; Furtak et al. 2007 ;
Hirai et al. 2012). In addition to being expressed in the
prefrontal cortex, s receptors are also located in the
amygdala (Hayashi et al. 2010) and may play a modulatory role on cognition in these areas (Wang et al. 2007).
The role of the hippocampus in object recognition remains controversial ; however, the putative role is believed to be evoked when spatial cues or landmarks
present in the room are used by animals while in the
testing chamber (Morris & Frey, 1997). Since our object
recognition testing chamber was enclosed within curtains, the eﬀects of distal landmarks and the role of the
hippocampus in our behavioural protocol can therefore
be minimized.
Consistent with the result in object recognition, treatment with methamphetamine in the absence or presence
of AZ66 produced a similar trend to memory changes in
the step-through passive avoidance test, although the
data were not statistically signiﬁcant. Dopamine plays
a strong role in diﬀerent brain regions involved with
the regulation of inhibitory avoidance memory. In the
striatum, pharmacological blockade of dopamine receptors impairs step-through passive avoidance memory
(Manago et al. 2009). Dopamine infused into the amygdala post-training enhances memory, while dopamine
receptor antagonists impair memory retention in the
passive avoidance test (Lalumiere et al. 2004). In addition,
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Fig. 5. Eﬀects of AZ66 (AZ) on methamphetamine (Meth)induced cognitive impairment in the step-through passive
avoidance test. Mice were pretreated with saline (Sal) or AZ
(10 mg/kg i.p.). After 15 min, the mice were then treated with Sal
or Meth (5 mg/kg i.p.). This treatment schedule was repeated
four times at 2 h intervals. One week later, the animals
underwent the step-through passive avoidance test. Animals
were observed for (a) % entries into the dark compartment
during training and (b) latency to enter dark compartment. Data
were reported as mean¡S.E.M., no signiﬁcant changes were
observed ; n=10 per group.

the dopamine uptake inhibitor GBR 12783 injected before
training signiﬁcantly improves passive avoidance memory in rats (Nail-Boucherie et al. 1998). One reason for the
lack of signiﬁcant results may be due to the strength of
emotional memory created by our behavioural paradigm.
Emotional or fear memory is one of the strongest forms of
memory and also the easiest to learn. In our behavioural
protocol, the mice received a moderately large intensity
and duration of footshocks (0.4 mA/5 s). While this
makes the training portion of the protocol easier, it can
also have an eﬀect of making the memory stronger in all
of the treatments, resulting in a response that can mask
the promnesic eﬀects of the experimental variable or
treatment (Nail-Boucherie et al. 1998 ; Rossato et al. 2009).
It is possible that training animals with lower intensity
and shorter duration of shocks (e.g. 0.3 mA/2–3 s) may
cause less ‘extreme ’ memory and thus allow more signiﬁcance to be observed 24 h later during our testing
paradigm. Nevertheless, our results, taken with the object
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